


Docket No. 284394US0PCT



IPW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Antoni TORRENS JOVER, et al.

SERIAL NO: 10/566,399

GAU: 1614

FILED: September 26, 2006

EXAMINER:

FOR: 2'-4-(HYDROXYMETHYL-PHENYLAMINO) -PIPERIDINE-1-YL!-N- (9H-CARBAZOL-3-YL) - ACETAMINE DERIVATIVES AND RELATED COMPOUNDS AS NEUROPEPTIDE Y5 (NPY5) LIGANDS FOR THE TREATMENT OF OBESITY

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The applicant(s) wish to make of record the reference(s) listed on the attached form PTO-1449. Copies of the listed reference(s) are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language reference(s).
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.
Norman F. Oblon

Paul J. Killos
Registration No. 58,014

Customer Number

22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 05/03)



Docket No. 284394US0PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Antoni TORRENS JOVER, et al.

SERIAL NO: 10/566,399

GAU: 1614

FILED: September 26, 2006

EXAMINER:

FOR: 2'-4-(HYDROXYMETHYL-PHENYLAMINO) -PIPERIDINE-1-YL!-N- (9H-CARBAZOL-3-YL) - ACETAMINE
DERIVATIVES AND RELATED COMPOUNDS AS NEUROPEPTIDE Y5 (NPY5) LIGANDS FOR THE
TREATMENT OF OBESITY

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The applicant(s) wish to make of record the reference(s) listed on the attached form PTO-1449. Copies of the listed reference(s) are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language reference(s).
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.
Norman F. Oblon

Paul J. Killos
Registration No. 58,014

Customer Number

22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 05/03)

DOCKET NO.: 284394US0PCT

Page 1 of 1



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Antoni TORRENS JOVER, et al.

SERIAL NO: 10/566,399

GROUP: 1614

FILED: September 26, 2006

EXAMINER:

FOR: 2-'4-(HYDROXYMETHYL-PHENYLAMINO) -PIPERIDINE-1-YL!-N- (9H-CARBAZOL-3-YL) - ACETAMINE DERIVATIVES AND RELATED COMPOUNDS AS NEUROPEPTIDE Y5 (NPY5) LIGANDS FOR THE TREATMENT OF OBESITY

STATEMENT OF RELEVANCY

All the References mentioned on PTO Form 1449 are discussed in the Application Text

Form PTO 1449
(Modified)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY DOCKET NO.
284394US0PCTSERIAL NO.
10/566,399

LIST OF REFERENCES CITED BY APPLICANT

APPLICANT

Antoni TORRENS JOVER, et al.

FILING DATE

September 26, 2006

GROUP

1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AJ					
	AK					
	AL					
	AM					
	AN					

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

	AO	Kazuhiko TATEMOTO, et al. "NEUROPEPTIDE Y-A NOVEL BRAIN PEPTIDE WITH STRUCTURAL SIMILARITIES TO PEPTIDE YY AND PANCREATIC POLYPEPTIDE", NATURE, Vol. 296, April 15, 1982, Pages 659-660				
	AP	James F. FLOOD, et al. "MODULATION OF MEMORY PROCESSING BY NEUROPEPTIDE Y", BRAIN RESEARCH, Vol. 421, 1987, Pages 280-290				
	AQ	John P. REDROBE, et al. "MULTIPLE RECEPTORS FOR NEUROPEPTIDE Y IN THE HIPPOCAMPUS: PUTATIVE ROLES IN SEIZURES AND COGNITION", BRAIN RESEARCH, Vol. 848, 1999, Pages 153-166				
	AR	Markus HEILIG, et al. "ANXIOLYTIC-LIKE EFFECT OF NEUROPEPTIDE Y (NPY), BUT NOT OTHER PEPTIDES IN AN OPERANT CONFLICT TEST", REGULATORY PEPTIDES, Vol. 41, 1992, Pages 61-69				
	AS	Martin C. MICHEL, et al. "NEUROPEPTIDE Y: A POSSIBLE ROLE IN HYPERTENSION?", JOURNAL OF HYPERTENSION, Vol. 13, No. 4, 1995, Pages 385-395				
	AT	Donald R. GEHLERT, "SUBTYPES OF RECEPTORS FOR NEUROPEPTIDE Y: IMPLICATIONS FOR THE TARGETING OF THERAPEUTICS", LIFE SCIENCES, Vol. 55, No. 8, 1994, Pages 551-562				
	AU	Philip HIPSKIND, et al. "NEUROPEPTIDE Y: AT THE DAWN OF SUBTYPE SELECTIVE ANTAGONISTS", ANNUAL REPORTS ON MEDICINAL CHEMISTRY, Vol. 31 Pages 1-10				
	AV	Lars GRUNDEMAR, et al. "NEUROPEPTIDE Y EFFECTOR SYSTEMS: PERSPECTIVES FOR DRUG DEVELOPMENT", TIPS REVIEWS, Vol. 15, May 1994, Pages 153-159				
	AW	Yinghe HU, et al. "IDENTIFICATION OF A NOVEL HYPOTHALAMIC NEUROPEPTIDE Y RECEPTOR ASSOCIATED WITH FEEDING BEHAVIOR", THE JOURNAL OF BIOMEDICAL CHEMISTRY, Vol. 271, No. 42, October 18, 1996, Pages 26315-26319				
	AX	Nigel R. LEVENS, et al. "NEUROPEPTIDE Y Y5 RECEPTOR ANTAGONISTS AS ANTI-OBESITY DRUGS", CURRENT OPINION IN INVESTIGATIONAL DRUGS, Vol. 4, No. 10, 2003, Pages 1198-1204				<input checked="" type="checkbox"/> Additional References sheet(s) attached

Examiner

Date Considered

*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 284394US0PCT		SERIAL NO. 10/566,399	
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT Antoni TORRENS JOVER, et al.			
				FILING DATE September 26, 2006		GROUP 1614	
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
	AY	Andrew V. TURNBULL, et al. "SELECTIVE ANTAGONISM OF THE NPY Y5 RECEPTOR DOES NOT HAVE A MAJOR EFFECT ON FEEDING IN RATS", DIABETES, Vol. 51, August 2002, Pages 2441-2449					
	AZ	O. DELLA-ZUANA, et al. "A POTENT AND SELECTIVE NPY Y ₅ ANTAGONIST REDUCES FOOD INTAKE BUT NOT THROUGH BLOCKADE OF THE NPY Y ₅ RECEPTOR", INTERNATIONAL JOURNAL OF OBESITY, Vol. 28, 2004, Pages 628-639					
	AAA	Povl KROGSGAARD LARSEN, et al. "A TEXTBOOK OF DRUG DESIGN AND DEVELOPMENT", Pages 630-643					
	AAB	J.F.W. MCOMIE, "PROTECTIVE GROUPS IN ORGANIC CHEMISTRY", 1973, 15 pages					
	AAC	Theodora W. GREENE, et al. "PROTECTIVE GROUPS IN ORGANIC SYNTHESIS" 1991, 3 pages					
	AAD	M.E. AULTON, "THE SCIENCE OF DOSAGE FORMS", PHARMACEUTICS, 2 nd EDITION, 2002, pages					
	AAE	James SWARBRICK, et al. "THE ENCYCLOPEDIA OF PHARMACEUTICAL TECHNOLOGY, 2nd EDITION, 2002, two pages and pages xvii-xxi					
	AAF	Gilbert S. BANKER, et al. "MODERN PHARMACEUTICS", DRUGS AND PHARMACEUTICAL SCIENCES, Vol. 121, 4 th EDITION, 2002, 2 pages					
	AAG	Leon LACHMAN, et al. "THE THEORY AND PRACTICE OF INDUSTRIAL PHARMACY", 3 rd EDITION, 1986, 2 pages					
	AAH	Michael RATHBONE, et al. "MODIFIED-RELEASE DRUG DELIVERY TECHNOLOGY", DRUGS AND THE PHARMACEUTICAL SCIENCES, Vol. 126, 2002, 9 pages					
	AAI	Stephen D. BRUCK, "CONTROLLED DRUG DELIVERY", BASIC CONCEPTS, Vol. 1, 1983, 3 pages					
	AAJ	Kanji TAKADA, et al. "ORAL DRUG DELIVERY, TRADITIONAL", 1999, Pages 728-742					
	AAK	Joseph FIX, "ORAL DRUG DELIVERY, SMALL INTESTINE AND COLON", 1999 Pages 698-728					
	AAL						
	AAM						
	AAN						
	AAO						
Examiner						Date Considered	
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							